Crispr Therapeutics AG vs Unilever plc — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while Unilever plc trades at $61.89 (market cap $134.06B). The key difference: Unilever plc is far larger — about 25.6× Crispr Therapeutics AG's market cap, and Unilever plc pays a 3.65% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | UL | |
|---|---|---|
Market Cap | $5.23B | $134.06B |
Sector | Health | Consumer Staples |
52-Week High | $76.78 | $74.59 |
52-Week Low | $44.34 | $55.05 |
Enterprise Value | $3.65B | $159.86B |
Dividend Yield | — | 3.65% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →